MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI S.GANDHISELVAN)
(a): As per inputs given by the Department of Health Research; there is no definite evidence available as yet that HIV virus has been evolving in the country since decade. But a recent article published in the Journal of Biological Chemistry reports increase in HIV strains with additional NFkB sites in the promoter region. (Source: Bachu et al, Multiple NF-?B sites in HIV-1 subtype C LTR confer superior magnitude of transcription and thereby the enhanced viral predominance. J. Biol. Chem. jbc.M112.397158. First Published on November 6, 2012. In press.)
(b): As per inputs given by the Department of Health Research; There is no evidence at this point of time that the evolution of HIV strains within the country would pose any additional threat.
(c): National AIDS Control Organisation has given a strong emphasis to strengthening of research activities under the programme. Research is a vital component of Strategic Information Management Unit under National AIDS Control Programme. Research in HIV/AIDS is promoted and coordinated by National AIDS Control Organisation in collaboration with Indian Council of Medical Research (ICMR). National AIDS Control Organisation focuses on ensuring translation of research outputs into programmatic action and policy formulation.
The amount spent on research and development by National AIDS Control Organisation on research projects undertaken and financial aid provided during the last three years is as follows:
Year Amount spent (In Rs.)
2009-10 Rs 2,00,76,137
2010-11 Rs 86,67,193
2011-12 Rs 79,42,024
2012-13 till date Rs 1,54,62,124
Total Rs 5,21,47,478
The same information pertaining to different institutes - State & UT âwise is provided in Annexure I. As per inputs
provided by Department of Biotechnology (DBT) under Ministry of Science & Technology, the amount spent on research
projects undertaken and financial aid provided during the last three years is as follows:
Year Amount spent (In Rs.)
2009-10 Rs 3,75,85,000
2010-11 Rs 4,72,34,200
2011-12 Rs 46,44,94,600
2012-13 till date Rs 13,82,15,200
Total Rs 68,75,29,000
The same information pertaining to different institutes - State & UT âwise is provided in Annexure II.
As per inputs provided by the Department of Health Research (DHR), the amount spent on research projects
undertaken and financial aid provided during the last three years is as follows:
Year Amount spent (In Rs.)
2009-10 Rs 7,43,89,389
2010-11 Rs 8,62,28,019
2011-12 Rs 1,28,932,243
2012-13 till date Rs 8,58,88,685
Total Rs 37,54,38,336
The details pertaining to different institutes - State & UT âwise is provided in Annexure III.
(d) & (e): As per inputs given by the Department of Health Research; Yes, National
AIDS Research Institute (NARI) has conducted two HIV vaccine trials in Pune.
These trials were conducted by National AIDS Research Institute (NARI), in collaboration with International AIDS Vaccine Initiative under a tripartite agreement between National AIDS Control Organisation-Indian Council of Medical Research and International AIDS Vaccine Initiative. National AIDS Research Institute (NARI) received a total grant of Rs. 6,60,81,568/- for this.
Details and outcomes of these vaccine trials:
1. AAV based Vaccine [A001]
This trial involved 24 volunteers who received vaccine and 6 as placebo. The vaccine was found to be safe and there were no adverse events associated with vaccine. However, the vaccine had poor immunogenicity and very low level of immune response was detected in small percentage of vaccine recipients. The vaccine could not be taken forward.
2. Prime and Boost Trial [P001] with DNA vaccine for priming and MAV for boost
This trial had two arms â one receiving DNA vaccine for priming and MVA for boost in comparison with other arm where recipients received MVA both for prime as well as boost. The vaccine was found to be safe and there were no significant
side effects. The vaccine induced good antibody response and cytotoxic T cell response. DNA-MVA arm showed better response than MVA alone arm. The issue related stability of MVA vaccine needs to be resolved before considering taking this vaccine forward.
(f): According to the Department of Health Research; It is not possible at this point to predict when vaccination is likely to be ready for mass use.